021-51111890
购物车（）
sales@molnova.cn
CK2/ERK8-IN-1
CAS No. 1085822-09-8
CK2/ERK8-IN-1 ( TMCB )
产品货号. M26119 CAS No. 1085822-09-8
CK2/ERK8-IN-1 是酪蛋白激酶 2 (CK2)（Ki：0.25 μM）和 ERK8（IC50：0.50 μM）的双重抑制剂，具有促凋亡功效。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥237 | 有现货 |
|
| 10MG | ￥374 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称CK2/ERK8-IN-1
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述CK2/ERK8-IN-1 是酪蛋白激酶 2 (CK2)（Ki：0.25 μM）和 ERK8（IC50：0.50 μM）的双重抑制剂，具有促凋亡功效。
-
产品描述CK2/ERK8-IN-1 is a dual inhibitor of casein kinase 2 (CK2) (Ki: 0.25 μM) and ERK8 (IC50s: 0.50 μM) with pro-apoptotic efficacy. CK2/ERK8-IN-1 also binds to PIM1, DYRK1A, and HIPK2 (Kis: 8.65 μM, 11.9 μM, and 15.25 μM).(In Vitro):In Jurkat cells, CK2/ERK8-IN-1 (Compound K66; 0-50 μM; 24 hours) treatment displays cytotoxic activity.
-
体外实验CK2/ERK8-IN-1 (Compound K66; 0-50 μM; 24 hours; Jurkat cells) treatment displays cytotoxic activity in Jurkat cells. Cell Viability Assay Cell Line:Jurkat cells Concentration:0-50 μM Incubation Time:24 hours Result:Inhibited cell growth in a dose-dependent manner.
-
体内实验——
-
同义词TMCB
-
通路Metabolic Enzyme/Protease
-
靶点Casein Kinase
-
受体RET
-
研究领域——
-
适应症——
化学信息
-
CAS Number1085822-09-8
-
分子量534.82
-
分子式C11H9Br4N3O2
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 16.67 mg/mL (31.17 mM)
-
SMILESO=C(O)CN1C2=C(Br)C(Br)=C(Br)C(Br)=C2N=C1N(C)C
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Alao JP, et al. Selective inhibition of RET mediated cell proliferation in vitro by the kinase inhibitor SPP86. BMC Cancer. 2014 Nov 20;14:853.
